{'fraction_non_alphanumeric': 0.04006608839322594, 'fraction_numerical': 0.03056588186699711, 'mean_word_length': 5.290909090909091, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial

Objective:To assess the effect of filgrastim treatment on the incidence of severe neutropenia in patients with advanced HIV infection, and the effect of initial filgrastim treatment on prevention of infectious morbidity. Design:Randomized, controlled, open-label, multicenter study. Setting:Outpatient centers and physician offices. Patients:Men and women aged > 13 years, who were HIV antibody-positive, and had a CD4 cell count < 200 × 106/l, absolute neutrophil count (ANC) 0.7−1.0 × 109/l, and platelet count ≥ 50 × 109/l within 7 days of randomization were eligible. Two hundred and fifty-eight patients entered and 201 completed the study. Intervention:Daily filgrastim (starting at 1 µg/kg daily, adjusted up to 10 µg/kg daily) or intermittent filgrastim (starting at 300 µg daily one to three times per week to a maximum of 600 µg daily 7 days weekly) was administered to maintain an ANC between 2 and 10 × 109/l. Patients in the control group received filgrastim if severe neutropenia developed. Main outcome measures:Incidence of severe neutropenia (ANC < 0.5 × 109/l) or death, incidence of bacterial and fungal infections, duration of hospitalization and intravenous antibacterial use, and safety. Results:The primary endpoint of severe neutropenia or death was less frequent in patients who received daily (12.8%) or intermittent (8.2%) filgrastim compared with control patients (34.1%; P < 0.002 and P < 0.0001 for comparison with daily and intermittent groups, respectively). Filgrastim-treated patients developed 31% fewer bacterial infections and 54% fewer severe bacterial infections than control patients, required 26% less hospital days including 45% fewer hospital days for bacterial infections, and needed 28% fewer days of intravenous antibacterials. Filgrastim was not associated with an increase in HIV-1 plasma RNA level in a subset of patients in whom this was measured or any new or unexpected adverse events. Conclusion:Filgrastim was safe and effective in preventing severe neutropenia in patients with advanced HIV infection, and may reduce the incidence and duration of bacterial infections, incidence of severe bacterial infections, duration of hospital days for infections, and days of intravenous antibacterial agents.